Generic Lipitor party over but olmesartan solid for Daiichi Sankyo
This article was originally published in Scrip
Executive Summary
Ranbaxy and its owner Daiichi Sankyo may have benefited handsomely from the 180-day first-to-file US exclusivity for the Indian firm's generic version of Lipitor (atorvastatin) when it was launched in December 2011, but the hangover is hitting with a vengeance this year.